S ETFs Trail Russell, CRSP Peers in Mid-Cap Race: CFRA
The iShares Core S&P Mid-Cap ETF (IJH) posted a 2.5% price return year to date, trailing the Vanguard Mid-Cap ETF (VO) at 8.2% and the iShares Russell Mid-Cap ETF (IWR) at 6.9% over the same period, according to the report. Similarly, the iShares Core S&P Small-Cap ETF (IJR) declined 2.1%, while the iShares Russell 2000 ETF (IWM) gained 1% and the Vanguard Small-Cap ETF (VB) climbed 1.9%.
Index Differences Explain Performance Divergence
The performance divergence stems from fundamental differences in how the indices define market-cap ranges, with S&P DJI indices tilting toward smaller companies while Russell and CRSP benchmarks capture relatively larger names that have benefited from the current mega-cap-driven market environment, according to CFRA.
Invest in Gold
American Hartford Gold: #1 Precious Metals Dealer in the Nation
Thor Metals Group: Best Overall Gold IRA
Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase
Index methodology differences explain the performance gaps between fund families, according to the research. The S&P MidCap 400 targets companies in the $8 billion to $22 billion market-cap range, while the CRSP U.S. Mid Cap Index covers the 70th to 85th percentile of total U.S. market cap and the Russell Midcap Index includes companies ranked 201 to 1,000 by market capitalization.
Several top-performing stocks held by VO and IWR are absent from IJH's portfolio, according to CFRA data. Palantir Technologies Inc. (PLTR), Robinhood Markets Inc. (HOOD), Roblox Corp. (RBLX) and Coinbase Global Inc. (COIN) contributed the most to IWR's returns but are not held by IJH, according to the report.
The performance gap reflects broader market dynamics that favor larger companies since the 2022 equity market recovery, according to CFRA. Palantir was added to the S&P 500 in September 2024 but only dropped from the CRSP and Russell mid-cap indices in 2025, giving those funds extended exposure to the stock's gains.
S&P Small-Cap Funds Face Similar Challenges
The same pattern emerges in small-cap funds, where S&P-linked ETFs underperform due to their narrower constituent base and smaller market-cap tilt, according to the research. The CRSP U.S. Small Cap Index targets the 85th to 99.5th percentile of total market cap, while the S&P SmallCap 600 covers the 93rd- to 99th-percentile range.
Stocks like NRG Energy Inc. (NRG) and Jabil Inc. (JBL) contributed to VB's outperformance but are held in the S&P 500 rather than the S&P SmallCap 600, according to CFRA. This gives VB a "large-cap boost" that IJR lacks in the current market environment.
Looking ahead, CFRA notes that S&P DJI-linked ETFs could outperform if market conditions shift to favor smaller companies over mega-caps. The firm's analysis suggests the performance differential will persist as long as larger market-cap companies continue outperforming their smaller counterparts.Permalink | © Copyright 2025 etf.com. All rights reserved
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Discovering Undiscovered Gems in the US Market August 2025
As the U.S. stock market navigates through a period of mixed performance with the Dow Jones Industrial Average reaching new highs while the S&P 500 and Nasdaq face declines, investors are keenly observing potential shifts in Federal Reserve policies that could impact future market dynamics. In this environment, identifying stocks with strong fundamentals and growth potential becomes crucial, especially as major indices fluctuate and economic indicators remain uncertain. Top 10 Undiscovered Gems With Strong Fundamentals In The United States Name Debt To Equity Revenue Growth Earnings Growth Health Rating Southern Michigan Bancorp 117.38% 8.87% 4.89% ★★★★★★ Oakworth Capital 87.50% 15.82% 9.79% ★★★★★★ ASA Gold and Precious Metals NA 12.79% -0.59% ★★★★★★ Sound Financial Bancorp 34.70% 2.11% -11.08% ★★★★★★ Metalpha Technology Holding NA 75.66% 28.60% ★★★★★★ First Northern Community Bancorp NA 8.05% 12.27% ★★★★★★ Senstar Technologies NA -20.82% 14.32% ★★★★★★ Valhi 44.30% 1.10% -1.40% ★★★★★☆ Pure Cycle 5.02% 4.35% -2.25% ★★★★★☆ Rich Sparkle Holdings 26.73% -6.13% 1.75% ★★★★★☆ Click here to see the full list of 286 stocks from our US Undiscovered Gems With Strong Fundamentals screener. Let's review some notable picks from our screened stocks. Carter Bankshares Simply Wall St Value Rating: ★★★★☆☆ Overview: Carter Bankshares, Inc. is the bank holding company for Carter Bank & Trust, offering a range of retail and commercial banking products and insurance services in the United States, with a market capitalization of $414.86 million. Operations: Carter Bankshares generates revenue primarily from its banking segment, totaling $153.12 million. Carter Bankshares, with assets totaling US$4.8 billion and equity of US$405.6 million, has been making waves recently. The company reported a significant earnings growth of 152.5% over the past year, outperforming the industry average of 12.5%. Despite this impressive performance, it grapples with a high level of bad loans at 6.7%, coupled with an insufficient allowance for bad loans at 28%. Recently added to multiple Russell indexes and completing a share buyback worth US$10.41 million for 171,899 shares, CARE seems poised for continued attention in investment circles due to its strong earnings momentum and strategic moves. Delve into the full analysis health report here for a deeper understanding of Carter Bankshares. Learn about Carter Bankshares' historical performance. Northrim BanCorp Simply Wall St Value Rating: ★★★★★★ Overview: Northrim BanCorp, Inc. is the bank holding company for Northrim Bank, offering commercial banking products and services to businesses and professional individuals, with a market cap of $476.66 million. Operations: Northrim BanCorp generates revenue primarily through its Community Banking segment with $121.89 million, followed by Home Mortgage Lending at $35.57 million and Specialty Finance contributing $6.39 million. Northrim BanCorp, with assets totaling US$3.2 billion and equity of US$290.2 million, stands out for its robust financial health. The company boasts total deposits of US$2.8 billion against loans of US$2.2 billion, indicating a solid funding base primarily from customer deposits—considered low risk compared to external borrowing. Its allowance for bad loans is sufficient at 190%, covering non-performing loans which are just 0.5% of total loans, well within acceptable limits. Recent earnings growth was impressive at 39%, far surpassing the industry average of 12%. Northrim's inclusion in multiple Russell indices highlights its recognition as a promising player in the market landscape. Get an in-depth perspective on Northrim BanCorp's performance by reading our health report here. Examine Northrim BanCorp's past performance report to understand how it has performed in the past. Shore Bancshares Simply Wall St Value Rating: ★★★★★★ Overview: Shore Bancshares, Inc. functions as a bank holding company for Shore United Bank, N.A., with a market capitalization of $525.66 million. Operations: Shore Bancshares generates revenue primarily from its community banking segment, which reported $208.21 million. Shore Bancshares, with total assets of US$6.0 billion and equity of US$565.2 million, presents a robust financial profile. Its net interest margin stands at 3.1%, supported by total deposits of US$5.3 billion and loans amounting to US$4.8 billion. The bank maintains a sufficient allowance for bad loans at 344% coverage, with non-performing loans at just 0.3%. Trading at a price-to-earnings ratio of 9.9x, it offers good value compared to the broader market's 18.8x average, while its earnings growth last year outpaced the industry significantly by reaching an impressive 166%. Dive into the specifics of Shore Bancshares here with our thorough health report. Gain insights into Shore Bancshares' past trends and performance with our Past report. Key Takeaways Take a closer look at our US Undiscovered Gems With Strong Fundamentals list of 286 companies by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Seeking Other Investments? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CARE NRIM and SHBI. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 days ago
- Yahoo
What Makes Crispr Therapeutics Ag (CRSP) a Good Buy?
RGA Investment Advisors, an investment management company, has released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter-end figures concealed the inherent volatility in the market, which began with a steep sell-off and ended with clarity around global trade that changed the environment for evaluating enterprises. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its second-quarter 2025 investor letter, RGA Investment Advisors highlighted stocks such as CRISPR Therapeutics AG (NASDAQ:CRSP). CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing company. The one-month return of CRISPR Therapeutics AG (NASDAQ:CRSP) was -8.57%, and its shares gained 19.87% of their value over the last 52 weeks. On August 15, 2025, CRISPR Therapeutics AG (NASDAQ:CRSP) stock closed at $59.73 per share, with a market capitalization of $5.432 billion. RGA Investment Advisors stated the following regarding CRISPR Therapeutics AG (NASDAQ:CRSP) in its second quarter 2025 investor letter: "After commercial approval of Casgevy, CRISPR Therapeutics AG (NASDAQ:CRSP) shares traded over $90. At their worst in the April crash, shares changed hands at $30, a 2/3rd discount to their post-approval peak. The trade war would ultimately have a negligible impact on CRSP, but shares dropped nearly 30% in the Spring collapse. This made little sense to us, especially given the substantial cash balance the company has built with prudent financings along the way. A laboratory cultivating cells for the development of gene and cell therapies. CRISPR Therapeutics AG (NASDAQ:CRSP) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held CRISPR Therapeutics AG (NASDAQ:CRSP) at the end of the first quarter, which was 27 in the previous quarter. While we acknowledge the potential of CRISPR Therapeutics AG (NASDAQ:CRSP) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered CRISPR Therapeutics AG (NASDAQ:CRSP) and shared the list of stocks Jim Cramer weighed in on. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
3 days ago
- Associated Press
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Luminar Technologies, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - August 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Luminar Technologies, Inc. (NASDAQ: LAZR) between March 20, 2025 and May 14, 2025, both dates inclusive (the 'Class Period'), of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Luminar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Luminar class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Austin Russell ('Russell'), Luminar's President, CEO and Chairman of the Board, was engaged in undisclosed conduct that would make him the subject of an inquiry by the Audit Committee of the Board of Directors; (2) this conduct created material risk that Russell would be released form his positions at Luminar; (3) Luminar's loss of Russell as an employee would then create material risk of adversely affecting Luminar's business by making it more difficult to compete with other market participants, manage R&D activities, and retain existing customers or cultivate new ones. Further, negative public perception and negative news related to Russell could adversely affect Luminar's brand relationships with customers, or standing in the industry; (4) accordingly, Luminar had no reasonable basis to provide and/or maintain Luminar's financial guidance; and (5) as a result, defendants' public statements were materially false and/or misleading at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Luminar class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
